Want to see SE:EGTX full AI Analyst Report?
Top Page
Egetis Therapeutics AB
(EGTX)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr10.00
Action:Reiterated
Date:09/30/26
The score is held down primarily by weak financial performance—substantial ongoing losses and significant cash burn—despite some revenue improvement and a recovering gross margin. Technicals are a relative positive with the price above major moving averages, but valuation remains challenging given the negative P/E and no dividend yield data.
Positive Factors
Rare-disease focus
A focused rare-disease strategy targets serious conditions where unmet need is high, which can support differentiated products and specialist adoption. Late-stage development and commercialization efforts may also provide a clearer path to durable revenue than an entirely early-stage pipeline.
Negative Factors
Heavy cash burn
Large negative operating and free cash flow shows that the business is not self-funding and remains dependent on external financing or cash reserves. Continued burn can restrict investment flexibility and increase funding needs if revenue growth does not materially narrow the gap.
Read all positive and negative factors
Positive Factors
Negative Factors
Rare-disease focus
A focused rare-disease strategy targets serious conditions where unmet need is high, which can support differentiated products and specialist adoption. Late-stage development and commercialization efforts may also provide a clearer path to durable revenue than an entirely early-stage pipeline.
Read all positive factors
Egetis Therapeutics AB (EGTX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr4.58B
Dividend YieldN/A
Average Volume (3M)2.98M
Price to Earnings (P/E)―
Beta (1Y)-0.38
Revenue Growth39.45%
EPS Growth-1.02%
CountrySE
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.01
Shares Outstanding464,947,240
10 Day Avg. Volume7,178,406
30 Day Avg. Volume2,984,653
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr33.00Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.61
Revenue Forecast (FY)kr664.60M
Egetis Therapeutics AB Business Overview & Revenue Model
Company Description
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan dru...
Egetis Therapeutics AB Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.10M | 62.40M | 46.10M | 57.60M | 22.50M | 38.24M |
| Gross Profit | 11.10M | 12.40M | 34.50M | -146.90M | -120.10M | -58.28M |
| EBITDA | -379.60M | -343.20M | -317.30M | -319.10M | -191.00M | -101.90M |
| Net Income | -405.50M | -342.50M | -343.60M | -326.90M | -189.50M | -104.73M |
Balance Sheet | ||||||
| Total Assets | 760.50M | 639.10M | 792.30M | 760.20M | 561.10M | 569.27M |
| Cash, Cash Equivalents and Short-Term Investments | 378.40M | 215.80M | 351.00M | 303.30M | 127.70M | 143.97M |
| Total Debt | 68.80M | 90.60M | 117.40M | 113.00M | 2.70M | 4.20M |
| Total Liabilities | 278.90M | 300.40M | 299.40M | 214.60M | 54.90M | 42.23M |
| Stockholders Equity | 481.50M | 338.70M | 492.80M | 545.60M | 506.20M | 527.04M |
Cash Flow | ||||||
| Free Cash Flow | -301.30M | -268.60M | -227.90M | -278.40M | -173.50M | -130.28M |
| Operating Cash Flow | -300.30M | -267.10M | -227.90M | -278.40M | -173.50M | -130.11M |
| Investing Cash Flow | -2.70M | -2.80M | -1.20M | -100.00K | -1.70M | -5.96M |
| Financing Cash Flow | 474.00M | 140.00M | 270.90M | 458.90M | 155.70M | -8.90M |
Egetis Therapeutics AB Technical Analysis
Positive
―
Price Trends
7.76
Positive
6.86
Positive
6.10
Positive
Market Momentum
0.53
Negative
71.85
Negative
91.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EGTX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 8.39, equal to the 50-day MA of 7.76, and equal to the 200-day MA of 6.10, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 71.85 is Negative, neither overbought nor oversold. The STOCH value of 91.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:EGTX.
Egetis Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Egetis Therapeutics AB Corporate Events
Egetis Therapeutics Adjusts Share Composition After Employee Stock Option Exercise
Sep 30, 2026
Egetis Therapeutics has reported changes in the composition of its share and vote structure for September following the exercise of employee stock options under its 2022–2026 and 2023–2026 programs. While the total number of shares and...
Egetis Wins First U.S. FDA Approval for MCT8 Deficiency Therapy EMCITATE
Sep 28, 2026
Egetis Therapeutics has received U.S. FDA approval for EMCITATE (tiratricol), the first and only treatment in the United States for peripheral thyrotoxicosis in adults and children with MCT8 deficiency, a severe and life-limiting X-linked thyroid ...
Egetis to Present New Emcitate Data at Major European Endocrinology Meetings
Sep 4, 2026
Egetis Therapeutics will showcase new clinical data for Emcitate, its thyroid hormone analogue tiratricol for MCT8 deficiency, at two major endocrinology conferences in Europe this September. The data from the Triac Trial II and ReTRIACt studies w...
Egetis Steps Up Investor Outreach Ahead of Key FDA Decision
Sep 3, 2026
Egetis Therapeutics will showcase its progress to investors at two major New York healthcare conferences in September, where CEO Nicklas Westerholm is scheduled for fireside chats and one-on-one meetings, with sessions available via webcast. The i...
Egetis Wins Japanese Orphan Status for Emcitate in Rare MCT8 Disorder
Aug 31, 2026
Egetis Therapeutics’ partner Fujimoto Pharmaceutical has secured orphan drug designation in Japan for Emcitate (tiratricol) in MCT8 deficiency, strengthening the product’s regulatory footing across major markets. The Japanese status br...
Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
Aug 21, 2026
Egetis Therapeutics reported second-quarter 2026 net revenue of SEK 17.4 million from Emcitate sales in Europe, up 23% at constant exchange rates versus a year earlier, while posting a quarterly loss of SEK 108.9 million as it invests in U.S. laun...
Egetis sets Q2 2026 results date as Emcitate nears key FDA decision
Aug 7, 2026
Egetis Therapeutics will publish its second-quarter 2026 report on August 21 and host a same-day conference call offering a corporate and financial update, followed by a QA session, with participation available via webcast or teleconference and a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.